PCV21 Pneumonia Protection: Children & Teens at Higher Risk
- A phase 3 trial (STRIDE-13) showed the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive; Merck) demonstrated robust immune responses and noninferiority to the pneumococcal 23-valent polysaccharide vaccine...
- PCV21 targets serotypes causing most invasive pneumococcal disease (IPD) in adults and is indicated for preventing invasive disease and pneumonia caused by 21 Streptococcus pneumoniae serotypes in individuals...
- The STRIDE-13 trial involved 882 participants with conditions increasing IPD risk (diabetes, chronic liver/lung/heart/kidney disease).
A phase 3 trial (STRIDE-13) showed the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive; Merck)
demonstrated robust immune responses and noninferiority to the pneumococcal 23-valent polysaccharide vaccine
(PPSV23) in high-risk children and adolescents (2 to <18 years) who had previously completed a pneumococcal
vaccine series.
PCV21 targets serotypes causing most invasive pneumococcal disease (IPD) in adults and is indicated for
preventing invasive disease and pneumonia caused by 21 Streptococcus pneumoniae serotypes in individuals
aged 18 and older.
The STRIDE-13 trial involved 882 participants with conditions increasing IPD risk (diabetes, chronic liver/lung/heart/kidney
disease). Participants received either PCV21 or PPSV23 after completing a primary pediatric pneumococcal vaccine.
Results showed PCV21 was immunogenic for all 21 serotypes 30 days post-vaccination, with immune responses
noninferior to PPSV23 for shared serotypes.